|
US$1679.00 · In stock Delivery: <= 9 days. True-PDF full-copy in English will be manually translated and delivered via email. YY/T 1787-2021: (Cardiovascular disease heart valve repair surgery and delivery system) Status: Valid
| Standard ID | Contents [version] | USD | STEP2 | [PDF] delivered in | Standard Title (Description) | Status | PDF |
| YY/T 1787-2021 | English | 1679 |
Add to Cart
|
9 days [Need to translate]
|
(Cardiovascular disease heart valve repair surgery and delivery system)
| Valid |
YY/T 1787-2021
|
Standard similar to YY/T 1787-2021
Basic data | Standard ID | YY/T 1787-2021 (YY/T1787-2021) | | Description (Translated English) | (Cardiovascular disease heart valve repair surgery and delivery system) | | Sector / Industry | Medical Device & Pharmaceutical Industry Standard (Recommended) | | Word Count Estimation | 83,834 | | Issuing agency(ies) | State Drug Administration |
YY/T 1787-2021: (Cardiovascular disease heart valve repair surgery and delivery system)---This is a DRAFT version for illustration, not a final translation. Full copy of true-PDF in English version (including equations, symbols, images, flow-chart, tables, and figures etc.) will be manually/carefully translated upon your order.
(Cardiovascular disease heart valve repair surgery and delivery system)
ICS 11.040.40
C35
People's Republic of China Pharmaceutical Industry Standard
Cardiovascular Implants
Heart valve repair device and delivery system
Published on 2021-09-06
2022-09-01 Implementation
Released by the State Drug Administration
directory
Preface I
1 Scope 1
2 Normative references 1
3 Terms and Definitions 2
4 Abbreviations 10
5 Basic requirements11
6 Device Description 11
7 Design Verification Experiments and Analysis/Design Validation 14
Appendix A (informative appendix) Principles of the provisions of this standard 22
Appendix B (Informative) Hazards, Relevant Failure Modes, and Evaluation Methods of Heart Valve Repair Systems 24
Appendix C (Informative) Guidelines for In Vitro Testing of Pediatric Devices 31
Appendix D (Normative Appendix) Packaging 33
Appendix E (Normative Appendix) Product Labels, Instructions for Use and Training 34
Appendix F (Normative Appendix) Sterilization 37
Appendix G (Informative) Characteristics of Heart Valve Repair Systems 38
Appendix H (informative) Examples and definitions of some physical and material properties of heart valve repair devices and their components42
Appendix I (Informative) Standard Examples for Testing Materials and Components for Heart Valve Repair Devices 52
Appendix J (informative) Considerations for changes in device material properties after implantation55
Appendix K (informative) Corrosion Assessment 56
Appendix L (Informative Appendix) Guidelines for In Vitro Evaluation of Restorative Functional Performance 59
Appendix M (Informative) Fatigue Assessment 63
Appendix N (Informative Appendix) Durability Test 68
Appendix O (Informative) Guidelines for Design Evaluation of Delivery Systems 70
Appendix P (Informative) Additional Device Design Evaluation Requirements 72
Appendix Q (Informative) Preclinical In Vitro Performance Evaluation of Annuloplasty Rings 74
Appendix R (Informative) Preclinical In Vivo Evaluation 75
Reference 78
foreword
This standard was drafted in accordance with the rules given in GB/T 1.1-2009.
This standard uses the redrafted method to modify the ISO 5910.2018 "Cardiovascular Implants and Heart Valve Repair of Extracorporeal Circulation Systems"
instrument". The technical differences between this standard and ISO 5910.2018 and their reasons are as follows.
--- Regarding normative reference documents, this standard has made adjustments with technical differences to adapt to the technical conditions of our country and the circumstances of the adjustment.
The situation is reflected in Chapter 2 "Normative References", and the specific adjustments are as follows.
● Replace ISO 10993-1 with GB/T 16886.1 which is equivalent to adopting international standards (see 7.2.3.2);
● Replace ISO 10993-2 with GB/T 16886.2 which is equivalent to adopting international standards (see 7.3.2);
● Replace ISO 17665-1 with GB 18278.1 which is equivalent to adopting international standards (see F.1);
● Replace ISO 11135-1 with GB 18279.1 which is equivalent to adopting international standards (see F.1);
● Replace ISO 11137 (all parts) with GB 18280 (all parts), the degree of consistency between the parts of the two standards
as follows.
◆ GB 18280.1-2015 Sterilization Radiation for Healthcare Products Part 1.Development of Sterilization Process for Medical Devices
requirements for development, validation and general control (ISO 11137-1.2006, IDT);
◆ GB 18280.2-2015 Sterilization Radiation for Healthcare Products Part 2.Establishing Sterilization Dose (ISO 11137-
2.2006,IDT);
◆ GB 18280.3-2015 Sterilizing Radiation for Healthcare Products Part 3.Guidelines for Dosimetry (ISO 11137-
3.2006,IDT);
● Replace ISO 11607 (all parts) with GB/T 19633 (all parts), the consistency process between the parts of the two standards
The degrees are as follows.
◆ GB/T 19633.1-2015 Packaging of Terminally Sterilized Medical Devices Part 1.Materials, Sterile Barrier Systems and Packaging
System requirements (ISO 11607-1.2006, IDT);
◆ GB/T 19633.2-2015 Packaging for Terminally Sterilized Medical Devices Part 2.Forming, Sealing and Assembly Processes
recognized requirements (ISO 11607-2.2006, IDT);
● Replace ISO 14937 with GB/T.19974 which is equivalent to adopting international standards (see F.1);
● Replace ISO 13485 with YY/T 0287 which is equivalent to adopting international standards (see 6.4 and 7.1);
● Replace ISO 15223-1 with YY/T 0466.1 which is equivalent to adopting international standards (see E.1.1);
● Replace ISO 15223-2 with YY/T 0466.2 which is equivalent to adopting international standards (see E.1.1);
● Replace ISO 14630 with YY/T 0640 which is equivalent to adopting international standards (see 6.2.1, 7.2.3.1, 7.3.1, D.1, E.1.1, and
F.1);
● Replace ISO 17664 with YY/T 0802 which is equivalent to adopting international standards (see F.1);
● Replace ISO 14160 with YY 0970 which is equivalent to adopting international standards (see F.1);
● Replace the revised version of ISO 14971.2007 with YY/T 0316-2016 which is equivalent to the international standard (see 3 and A.1);
● Replacing ISO 22442 (all parts) with YY/T 0771 (all parts), the degree of consistency between the parts of the two standards
as follows.
◆ YY/T 0771.1-2009 Medical Devices of Animal Origin Part 1.Application of Risk Management (ISO 22442-1.
2007, IDT);
◆ YY/T 0771.2-2009 Medical Devices of Animal Origin Part 2.Control of Source, Collection and Disposal (ISO
22442-2.2007,IDT);
◆ YY/T 0771.3-2009 Medical Devices of Animal Origin Part 3.Viral and Transmissible Spongiform Encephalopathy (TSE)
Validation of factor removal and inactivation (ISO 22442-3.2007, IDT);
◆ YY/T 0771.4-2015 Medical Devices of Animal Origin Part 4.Transmissible Spongiform Encephalopathy (TSE) Factors
Principles for analysis of removal and/or inactivation and their process confirmation (ISO /T R22442-4.2010, IDT);
--- Delete the part of 7.4 clinical research, "Technical Guidelines for Clinical Evaluation of Medical Devices" gives the relevant requirements for clinical trials.
This standard has made the following editorial changes.
--- Modify the standard name to "Cardiovascular Implants, Heart Valve Repair Devices and Delivery Systems", this standard does not include extracorporeal circulation
System related content;
--- Deleted Appendix B (Informative Appendix) "Examples of Heart Valve Repair Devices and Delivery Systems";
--- Delete Appendix Q (Informative Appendix) "Classification of Adverse Events During Clinical Research";
--- Delete Appendix R (informative appendix) "imaging scheme";
--- Deleted Appendix S (Informative Appendix) "Clinical Research Endpoints of Valve Repair Devices. Recommendations on Endpoints and Time";
--- Added Appendix Q (informative appendix) "Preclinical in vitro performance evaluation of annuloplasty rings".
Please note that some content of this document may be patented. The issuing authority of this document assumes no responsibility for identifying these patents.
This standard is proposed by the State Drug Administration.
This standard is approved by the National Technical Committee for Standardization of Surgical Implants and Orthopedic Devices Subcommittee on Cardiovascular Implants (SAC/TC
110/SC2) focal point.
This standard was drafted by. Tianjin Medical Device Quality Supervision and Inspection Center, State Drug Administration Medical Device Technical Review
Heart, Shanghai New Pulse Medical Technology Co., Ltd.
The main drafters of this standard. Miao Hui, Jiao Yongzhe, Duan Qingjiao, Shi Xinli, Liu Wei, Yu Qifeng, Wen Xiantao.
Cardiovascular Implants
Heart valve repair device and delivery system
1 Scope
This standard specifies the operating conditions and performance requirements for heart valve repair devices and their delivery systems, if applicable.
This standard applies to all repairs and/or modifications intended to act on valvular structures or adjacent anatomical structures (e.g., ventricles, coronary sinus).
Heart valve repair devices that improve the function of human native heart valves (for example. valvuloplasty devices, leaflet clamping devices, artificial tendons
Sow, etc.).
This standard does not apply to cardiac resynchronization therapy (CRT) devices, paravalvular leak closure devices, and non-implantable systems (eg, ablation,
radiofrequency valvuloplasty), apical catheters and instruments with living cell-containing components. Nor is the standard suitable for the intended use not repaired and/or modified
Materials that improve the function of human heart valves (eg. mesh materials and sutures for general surgery).
Note 1.YY/T 0640 specifies general requirements for the performance of passive surgical implants, this standard can be regarded as a supplement to YY/T 0640.
Note 2.This standard outlines a risk management approach to verify/validate the design and manufacture of heart valve repair systems. Choose the appropriate
Validation/validation tests and methods. Such tests include evaluation of the physical, chemical, biological and mechanical properties of the components and materials of the heart valve repair system.
Evaluate. The trial also includes a preclinical in vivo evaluation of the finished heart valve repair system to assess the safety and efficacy of the heart valve repair system.
effectiveness.
Note 3.Appendix A gives the rationale for the terms of this standard.
2 Normative references
The following documents are essential for the application of this document. For dated references, only the dated version applies to this article
pieces. For undated references, the latest edition (including all amendments) applies to this document.
GB/T 16886.1 Biological Evaluation of Medical Devices Part 1.Evaluation and Testing in Risk Management Process (GB/T 16886.
1-2011, ISO 10993-1.2009, IDT)
GB/T 16886.2 Biological Evaluation of Medical Devices Part 2.Animal Welfare Requirements (GB/T 16886.2-2011, ISO
10993-2.2006, IDT)
GB 18278.1 Moist heat for sterilization of health care products - Part 1.Requirements for the development, validation and routine control of the sterilization process for medical devices
Seek (GB 18278.1-2015, ISO 17665-1.2006, IDT)
GB 18279.1 Sterilization of Healthcare Products Ethylene Oxide Part 1.Development, Validation and Routine Control of Sterilization Processes for Medical Devices
requirements (GB 18279.1-2015, ISO 11135-1.2007, IDT)
GB 18280 (all parts) Sterilizing radiation for healthcare products [ISO 11137 (all parts)]
GB/T 19633 (all parts) Packaging for terminally sterilized medical devices [ISO 11607 (all parts)]
GB/T.19974 Characterization of Sterilization Factors for Sterilization of Healthcare Products and Development, Validation and Routine Control of Sterilization Processes for Medical Devices
General requirements for (GB/T.19974-2018, ISO 14937.2009, IDT)
YY/T 0287 Medical device quality management system for regulatory requirements (YY/T 0287-2017, ISO 13485.2016,
IDT)
YY/T 0316-2016 Application of Medical Device Risk Management to Medical Devices (ISO 14971.2007 Corrected Edition, IDT)
Tips & Frequently Asked Questions:Question 1: How long will the true-PDF of YY/T 1787-2021_English be delivered?Answer: Upon your order, we will start to translate YY/T 1787-2021_English as soon as possible, and keep you informed of the progress. The lead time is typically 6 ~ 9 working days. The lengthier the document the longer the lead time. Question 2: Can I share the purchased PDF of YY/T 1787-2021_English with my colleagues?Answer: Yes. The purchased PDF of YY/T 1787-2021_English will be deemed to be sold to your employer/organization who actually pays for it, including your colleagues and your employer's intranet. Question 3: Does the price include tax/VAT?Answer: Yes. Our tax invoice, downloaded/delivered in 9 seconds, includes all tax/VAT and complies with 100+ countries' tax regulations (tax exempted in 100+ countries) -- See Avoidance of Double Taxation Agreements (DTAs): List of DTAs signed between Singapore and 100+ countriesQuestion 4: Do you accept my currency other than USD?Answer: Yes. If you need your currency to be printed on the invoice, please write an email to [email protected]. In 2 working-hours, we will create a special link for you to pay in any currencies. Otherwise, follow the normal steps: Add to Cart -- Checkout -- Select your currency to pay.
|